NCT00237159已完成4 期
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 284
- 主要终点
- Rate of skeletal complications
研究概览
简要总结
It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
ZOL446
Experimental
干预措施: Zoledronic acid (Drug)
结局指标
主要结局
Rate of skeletal complications
时间窗: 3 months
次要结局
- Time to first skeletal complication(3 months)
- Bone pain(3 months)
- Patients´ satisfaction with treatment(3 months)
- Bone turnover parameters(3 months)
研究者
相似试验
已完成
4 期
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone MetastasisRenal Cell CancerNeoplasm MetastasisNCT00172003Novartis Pharmaceuticals50
招募中
不适用
Study of therapy with zoledronic acid in prostate cancer patients with bone metastases.Prostate CancerJPRN-UMIN000011442Osaka University Graduate School of Medicine,Department of Organ Specific Regulation (Urology)200
终止
1 期
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas CancerAdenocarcinomaNCT00892242Washington University School of Medicine24
已完成
4 期
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone MetastasesProstate CancerNCT00219219Novartis
已完成
4 期
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as BisphosphonatesProstate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is IndicatedNCT00172016Novartis Pharmaceuticals43